OncoMatch/Clinical Trials/NCT06577194
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
Is NCT06577194 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sintilimab + IL-2 Combined with CAPOX for rectal cancer.
Treatment: Sintilimab + IL-2 Combined with CAPOX — A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy with IL-2 Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Tumor Agnostic
Disease stage
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
Previous systemic anti-cancer treatment for colorectal cancer
Cannot have received: anti-PD-1 therapy
Previous treatment with anti-programmed death receptor-1 (PD-1) or its ligand (PD-L1) antibodies
Cannot have received: anti-PD-L1 therapy
Previous treatment with anti-programmed death receptor-1 (PD-1) or its ligand (PD-L1) antibodies
Cannot have received: anti-CTLA-4 therapy
Previous treatment with anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies
Lab requirements
Blood counts
neutrophil count ≥ 1.5×10^9/L; platelet count ≥ 75×10^9/L
Kidney function
serum creatinine ≤ 1.5× UNL
Liver function
serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL
Adequate hematological, liver, and kidney functions: neutrophil count ≥ 1.5×10^9/L; platelet count ≥ 75×10^9/L; serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL; serum creatinine ≤ 1.5× UNL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify